Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality 66% Improvement Relative Risk Ventilation 38% ICU admission -58% Hospitalization 24% c19early.org/pl Wong et al. Paxlovid for COVID-19 EARLY TREATMENT Favors paxlovid Favors control
Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Wong et al., The Lancet, doi:10.1016/S0140-6736(22)01586-0
8 Oct 2022    Source   PDF   Share   Tweet
PSM retrospective 1,074,856 outpatients in Hong Kong, showing lower mortality and hospitalization with paxlovid.
risk of death, 66.0% lower, HR 0.34, p < 0.001, treatment 5,542, control 54,672, propensity score matching.
risk of mechanical ventilation, 38.0% lower, HR 0.62, p = 0.36, treatment 5,542, control 54,672, propensity score matching.
risk of ICU admission, 58.0% higher, HR 1.58, p = 0.08, treatment 5,542, control 54,672, propensity score matching.
risk of hospitalization, 24.0% lower, HR 0.76, p < 0.001, treatment 5,542, control 54,672, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Wong et al., 8 Oct 2022, retrospective, China, peer-reviewed, 6 authors, study period 26 February, 2022 - 26 June, 2022.
Contact: carlosho@hku.hk, bcowling@hku.hk.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit